Artera was named one of TIME's World's Top HealthTech Companies for 2026 alongside other major industry accolades. This recognition validates the company's decade-long growth and leadership in healthcare patient communications.
In this lively interview, Guillaume de Zwirek, CEO & Co-Founder at Artera, lays out a vision for patient access where AI provides speedy handling, comprehensive gap coverage, and insightful feedback to providers at a level beyond what humans could do. De Zwirek offers an excellent, articulate summary of how AI can simplify patient access workflows […]
This analysis discusses Artera's pivot from a standard SaaS model to an 'AI Services' framework, where dedicated Agentic AI squads co-develop bespoke solutions for healthcare providers.
A weekly summary of Artera's strategic focus on deploying voice AI within clinical workflows, emphasizing measurable ROI and integration depth to strengthen its position in the healthcare communication market.
Atlantic Health has deployed Artera's AI agents to manage colonoscopy patient outreach, resulting in measurable improvements in appointment confirmation and patient engagement within the first 30 days.
Artera has partnered with Signify Research to release a new report providing a framework for healthcare leaders to evaluate AI voice solutions. This initiative positions Artera as a thought leader in the patient communication and healthtech space.
Artera commissioned an independent study by Signify Research to provide a framework for healthcare providers evaluating AI voice solutions. This positions Artera as a thought leader in the patient communication space and helps guide potential customers toward their specific technology.
Artera and Photocure have launched a joint research initiative to evaluate AI-powered digital pathology tests for bladder cancer. This partnership expands Artera's clinical footprint by integrating its precision medicine technology with Photocure's bladder cancer registry.
Photocure and Artera have launched a joint research initiative to validate the ArteraAI Bladder Test using Photocure's blue light cystoscopy registry data. This partnership aims to enhance precision medicine in uro-oncology by leveraging multimodal AI to improve bladder cancer treatment decisions.
Artera's Harmony Federal Edition platform has achieved FedRAMP Class D Certification, a significant security milestone that allows the company to expand its patient communication services to federal healthcare agencies like the VA and DoD.
Tempus AI and Artera have integrated the ArteraAI Prostate Test into the Tempus platform, providing clinicians with advanced digital pathology tools to personalize treatment for patients with metastatic hormone-sensitive prostate cancer.
Artera announced that its 'Artera Harmony Federal Edition' platform has achieved FedRAMP Authority to Operate, enabling the company to expand its patient communication and engagement services within federal healthcare agencies.
Headlines surfaced and scored by PortcoMonitor. Get the full, ranked feed + a daily briefing →